Related Experiment Video

Updated: Apr 9, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

3.3K

Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach

Stephen A Black1, Alexander T Cohen

  • 1Stephen Black, Department of Vascular Surgery, Guy's and St Thomas' Hospital, 1st Floor North Wing, 1 Westminster Bridge Road, London SE1 7EH, UK, Tel.: +44 207 188 2574, Fax: +44 207 188 1094,

Thrombosis and Haemostasis
|June 19, 2015
PubMed

Insights

Four non-vitamin K antagonist oral anticoagulants (NOACs) offer new venous thromboembolism (VTE) treatments. This review assesses NOAC trial data to guide tailored anticoagulant selection for improved patient outcomes.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hematology

Background:

  • Four non-vitamin K antagonist oral anticoagulants (NOACs) are now available for venous thromboembolism (VTE) treatment.
  • Clinical trials have established the efficacy and safety of these agents.
  • There is a growing need for personalized treatment recommendations in VTE management.

Purpose of the Study:

  • To review Phase III clinical trial data for NOACs in VTE treatment.
  • To assess the suitability of different NOACs for specific patient subgroups and VTE causes.
  • To present individualized risks of recurrent VTE and bleeding events.

Main Methods:

  • Systematic review of Phase III clinical trial data for NOACs.
  • Analysis of efficacy and safety outcomes across different patient populations.
  • Stratification of risks based on patient characteristics and VTE etiology.

Main Results:

  • NOACs demonstrate comparable or superior efficacy to traditional anticoagulants for VTE treatment.
  • Bleeding risks vary among NOACs and patient subgroups.
  • Specific NOACs may offer advantages in certain patient populations or etiological contexts.

Conclusions:

  • Tailored selection of NOACs based on individual patient risk factors and VTE characteristics is crucial.
  • Further research may refine optimal NOAC use for maximizing clinical benefits and minimizing risks.
  • Personalized anticoagulation strategies can improve VTE management outcomes.
Keywords:
Deep-vein thrombosisclinical trialsoral anticoagulantspulmonary embolismvenous thrombosis

More Related Videos

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

17.0K
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.2K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
391
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
676
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
441